Compared with healthy contralateral eyes, after 8 weeks of glaucoma and MT treatment, the RGC loss in the retinal center was 12% in the shRNA-control group compared with 36% in the shRNA-HuR group, while in the retinal periphery, it was 16% in the shRNA-control group compared with 38% in the shRNA-HuR group. This evidence concerns the gene ELAVL1 and glaucoma.